SCHEMBL5377229

SCHEMBL5377229

CC(C)(C)c1cc(C=C2C(=O)Nc3ccc(S(=O)(=O)Nc4ccc(C(F)(F)F)cc4)cc32)cc(Cl)c1OCc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.47
MOGAT2 Q3SYC2 1/20 0.46
MGAT2 Q10469 5/20 0.45
ERBB2 P04626 4/20 0.44
PRKDC P78527 1/20 0.41
EGFR P00533 3/20 0.41
IGF1R P08069 1/20 0.39
PGR P06401 1/20 0.38
LRRK2 Q5S007 1/20 0.38
RAF1 P04049 1/20 0.38
PSEN1 P49768 1/20 0.38
PSEN2 P49810 1/20 0.38
APH1B Q8WW43 1/20 0.38
NCSTN Q92542 1/20 0.38
APH1A Q96BI3 1/20 0.38
PSENEN Q9NZ42 1/20 0.38
MGAT1 P26572 1/20 0.37
MGAT3 Q09327 1/20 0.37
BRD4 O60885 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5403860 0.96 AR (0.50) ARMOGAT2MGAT2ERBB2PRKDC
SCHEMBL5376628 0.92 AR (0.47) ARMOGAT2MGAT2ERBB2PRKDC
SCHEMBL5358718 0.92 ERBB2 (0.49) ARMOGAT2MGAT2ERBB2PRKDC
SCHEMBL5364069 0.90 ERBB2 (0.54) MOGAT2MGAT2ERBB2EGFRLRRK2
SCHEMBL5361276 0.88 AR (0.49) ARMOGAT2MGAT2ERBB2PRKDC
SCHEMBL5373477 0.88 AR (0.52) ARMOGAT2MGAT2PRKDCLRRK2
SCHEMBL5369490 0.88 ERBB2 (0.47) ERBB2EGFRIGF1RLRRK2RAF1
SCHEMBL5367172 0.85 ERBB2 (0.54) MOGAT2MGAT2ERBB2EGFRIGF1R
SCHEMBL7139382 0.84 AR (0.64) ARMOGAT2MGAT2PGRPSEN1
SCHEMBL7136795 0.83 AR (0.57) ARMOGAT2MGAT2PRKDCPGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK AR 1805/4885MOGAT2 1159/4885MGAT2 4714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.